Figure 8.

Correlated with anti-CTLA4 and anti-PD-1 immunotherapy, drug screening, and drug IC₅₀ prediction. (A) Heat map exploring the response of anti-CTLA4 and anti-PD-1 immunotherapy for gastric adenocarcinoma in the high- and low-risk groups. CTLA4-noR, anti-CTLA4 immunotherapy did not respond; CTLA4-R, anti-CTLA4 immunotherapy responded, and so on. Including nominal P-value and Bonferroni corrected P-value. (B) Difference in the TIDE score between the high- and low-risk groups. (C) Structure of the small-molecule drug genistein. Genistein is a natural aromatic oxygenated heterocyclic compound, which can inhibit the expression of risk-model-related genes and lead to apoptosis of gastric cancer cells. (D) Differences in IC₅₀, estimated between the high- and low-risk groups, of 12 drugs that were conducive to reducing the risk of gastric adenocarcinoma and improving survival. TIDE, tumor immune dysfunction and exclusion; IC₅₀, half-maximal inhibitory concentration.